



Contact:  
CCG Elite Investor Relations  
Crocker Coulson, President  
Phone: +1-646-213-1915 (New York)  
Email: crocker.coulson@ccgir.com

*For Immediate Release*

## **China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter FY 2008 Results**

**Shanghai, China – November 8, 2007** – China-Biotics, Inc. (OTC BB: CHBT), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will conduct a conference call at 8:00 a.m. EST on Wednesday, November 14, 2007, to discuss the Company's financial results for the second quarter, ended September 30, of its 2008 fiscal year.

Hosting the call will be Jinan Song, Chairman and Chief Executive Officer, Raymond Li, Chief Financial Officer, and Henry Tai, Vice President of Corporate Development.

To participate in the event by telephone, please dial (800) 374-0113 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 23639406. International callers should dial (706) 758-9607.

A digital replay of the call will be available on Wednesday, November 14 at approximately 12:00 p.m. Eastern Time through Wednesday, November 21 at midnight Eastern Time. To listen to the replay dial (800) 642-1687 and enter the conference ID number 23639406. International callers should dial (706) 645-9291 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties by using the following link:

<http://phx.corporate-ir.net/playerlink.zhtml?c=192711&s=wm&e=1689295>. To listen to the call, please visit this link at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. For those unable to participate during the live webcast, it will be archived using the same link for 90 days.

## **About China-Biotics, Inc.**

China-Biotics, Inc. (“China-Biotics,” “the Company”), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the “Shining” brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand stores in major cities in China during the next two years. The Company’s flagship product, “Shining Essence,” was approved by the Chinese Ministry of Health for production and to market as a health product in August 2000, and it has been a profit driver since its launch in Shanghai in April 2001. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market.

*Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company’s ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

###